PET/MRI Perfusion and CT Perfusion in Solid Tumors

Diagnostic and Clinical Accuracy of Integrated Magnetic Resonance Imaging and Computed Tomography Perfusion in PET/MRI in Comparison to PET/CT in Solid Tumors

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02314962

Acronym

Perfusion

Enrollment

Registered

2014-12-11

Start date

2014-12-31

Completion date

2016-12-31

Last updated

2016-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CT Perfusion and MRI Perfusion in Solid Tumors

Brief summary

Diagnostic comparison between PET/CT and PET/MRI with integrated perfusion measurement in CT and MR. Study aim is to gain knowledge about additional value of CT perfusion and MR perfusion in solid tumors concerning tumor physiology, diagnostic accuracy and possibly prognostic.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

30 Years to 90 Years

Healthy volunteers

Inclusion criteria

* indication as stated above * written informed consent * patients with suspected or confirmed solid malignant tumors of the neck, chest or abdomen who have an indication for a PET/CT

Exclusion criteria

* pregnant or breast feeding women * non compliance of the patient to follow the study instructions (e.g. hearing problems, dementia) * Inclusion in another clinical trial 30 days prior to inclusion * age \< 30years * contraindication for MRI (cardiac pacemaker, certain metal implants, claustrophobia * known allergies to contrast CT or MRI contrast media * patients with an glomerular filtration rate of \< 60ml/min/1.73m2

Design outcomes

Primary

Measure	Time frame
Measurement of blood flow, blood volume and transfer constant (Ktrans) with CT-Perfusion and PET/MR-perfusion in solid tumors.	18 months

Secondary

Measure	Time frame
Correlation of blood flow, blood volume and transfer constant (Ktrans) measured with CT-Perfusion and PET/MR-perfusion with progression free survival in solid tumors.	18 months

Other

Measure	Time frame
Measurement of blood flow (mL/100 mg tissue/min) with CT-Perfusion and PET/MR-perfusion in solid tumors.	18 months
Measurement of blood volume (mL/100 mg tissue) with CT-Perfusion and PET/MR-perfusion in solid tumors.	18 months
Measurement of transfer constant with PET/MR-perfusion in solid tumors.	18 months

Countries

Switzerland

Outcome results